about
CCL2 DNA vaccine to treat renal disease.Tolerance induction by removal of alloreactive T cells: in-vivo and pruning strategies.P2X7 antagonism using Brilliant Blue G reduces body weight loss and prolongs survival in female SOD1G93A amyotrophic lateral sclerosis mice.DNA vaccine encoding CD40 targeted to dendritic cells in situ prevents the development of Heymann nephritis in rats.Selective depletion of alloreactive T cells leads to long-term islet allograft survival across a major histocompatibility complex mismatch in diabetic mice.Methyl-Guanine-Methyl-Transferase Transgenic Bone Marrow Transplantation Allows N,N-bis(2-chloroethyl)-Nitrosourea Driven Donor Mixed-Chimerism Without Graft-Versus-Host Disease, and With Donor-Specific Allograft Tolerance.DNA vaccination with CCL2 DNA modified by the addition of an adjuvant epitope protects against "nonimmune" toxic renal injury.Foxp3-transduced polyclonal regulatory T cells protect against chronic renal injury from adriamycin.The P2X7 receptor is not essential for development of imiquimod-induced psoriasis-like inflammation in mice.The P2X7 receptor antagonist Brilliant Blue G reduces serum human interferon-γ in a humanized mouse model of graft-versus-host disease.Transforming growth factor beta (TGFβ) plays a crucial role in prolonging allograft survival in an allodepletion ("pruning") skin transplant model.Single nucleotide primer extension (SNuPE) analysis of the G6PD gene in somatic cells and oocytes of a kangaroo (Macropus robustus)"Pruning" of alloreactive CD4+ T cells using 5- (and 6-)carboxyfluorescein diacetate succinimidyl ester prolongs skin allograft survivalActivation of the P2X7 receptor induces the rapid shedding of CD23 from human and murine B cellsAltered donor P2X7 activity in human leukocytes correlates with P2RX7 genotype but does not affect the development of graft-versus-host disease in humanised miceThe P2X7 receptor antagonist JNJ-47965567 administered thrice weekly from disease onset does not alter progression of amyotrophic lateral sclerosis in SOD1G93A miceLong-term treatment with the P2X7 receptor antagonist Brilliant Blue G reduces liver inflammation in a humanized mouse model of graft-versus-host diseaseIncreased splenic human CD4+:CD8+ T cell ratios, serum human interferon-γ and intestinal human interleukin-17 are associated with clinical graft-versus-host disease in humanized miceThe A2A receptor agonist CGS 21680 has beneficial and adverse effects on disease development in a humanised mouse model of graft-versus-host diseasePharmacological blockade of the CD39/CD73 pathway but not adenosine receptors augments disease in a humanized mouse model of graft-versus-host disease
P50
Q37259747-62E9AD52-4222-4687-8B74-D3B1C566C6A6Q37554216-1D3F9375-25C8-4C4D-B533-F661D38C6CC2Q37679001-7B076A0F-9F3E-468A-BC3C-DAF580D81E21Q43755601-FB22EA7C-331D-4A17-A0F3-7E1720EF41C8Q44188868-23154833-157F-4B2F-9BAF-287703053ACEQ45877690-DCC88F87-B28F-44C4-A871-B2D104F9DA12Q46882449-CFC0E90F-67CF-4058-B3E6-FBFDB44386CAQ46935287-13A8B265-8F5C-4970-A3F8-7B31019093B2Q47144272-454575B8-9173-404C-8FEF-4BF956FDD1E6Q48194542-C720B5AB-3B1B-4A21-80A0-BC1050D60B0FQ53056845-9D792F1A-36D7-4FD7-A3ED-25370478867FQ73996417-A0143BFD-8A5C-4F52-BE57-1443702FCBC4Q81040835-9190D327-D8A0-4424-89E6-602062C48AD5Q87655511-54752F2B-CCB4-4588-B06C-A80F4720627DQ90005205-776FC260-75A3-471B-A31D-B2DB8364E544Q90319920-503C0992-B68C-41E4-A8B9-6387E94389CDQ90460297-B675C0C7-8078-453C-ABE5-72F27BC6075CQ91455807-8B2678F3-2A66-41E2-9C9B-862E82400443Q91734967-5BCE2F99-4EB4-4AD0-9A56-B475B2CCEC13Q92917365-BFBE42EB-C5F0-4147-A928-5DEF3F872061
P50
description
researcher
@en
name
D Watson
@en
D Watson
@nl
type
label
D Watson
@en
D Watson
@nl
prefLabel
D Watson
@en
D Watson
@nl
P108
P106
P31
P496
0000-0002-6242-3944